ArticleJournal of managed care & specialty pharmacy2026
The Washington State Prescription Drug Affordability Board's selection of drugs for affordability review.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe Washington State Prescription Drug Affordability Board (PDAB) is tasked with conducting affordability reviews to identify whether prescription drugs have excess costs, defined as either exceeding therapeutic value or being unsustainable to public and private health care systems. The PDAB also has the authority to set upper payment limits (UPLs). There has been limited reporting of the methods and decisions through which PDABs examine and choose drugs for affordability review.
objectiveTo describe the processes of identifying drugs eligible for affordability review and selecting drugs for affordability review.
methodsBranded drugs are eligible for affordability review if their wholesale acquisition cost (WAC) was at least $60,000 or their price increased above certain thresholds. Biosimilar products are eligible if their price was not at least 15% lower than the reference biologic product. Generic drugs are eligible if their WAC was at least $100 per 30-day supply and increased by at least 200% in a 12-month period. Eligible drugs were ranked according to 4 criteria with the following weights: total out-of-pocket costs (0.35), total costs (0.33), mean out-of-pocket costs among users (0.19), and total number of users (0.13).
results290 drug products were eligible in the 2023 drug review cycle. The majority (n = 166) were branded drugs, which were eligible because their WAC for a course of treatment was at least $60,000. After the weighted ranking of eligible drugs, the board chose the top 4 drugs for affordability review: Enbrel, Xtandi, Humira, and Cabometyx.
conclusionsThe selected drugs have high cost burden for patients and payers in Washington. Affordability reviews of these drugs will evaluate whether they have led or will lead to excess costs, which will inform PDAB decisions regarding the possible implementation of UPLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.